DigestRedComo funciona
Red
/
Empresas
Me
No verificado

Merz Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
26/01/2026
Salud
Ir de compras
Jóvenes
Infancia
Farmacéutica
Industria
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity
Fuente
Merz Therapeutics
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Industria
Biotecnología
Farmacéutica
Salud
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 2026
Fuente
Merz Therapeutics
Editor
Business Wire
1.00
0
25/08/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Industria
Merz Therapeutics Announces First Patients Enrolled in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention
Fuente
Merz Therapeutics
Editor
Business Wire
1.00
0
17/12/2024
Industria
Material médico sanitario
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot
Fuente
Merz Therapeutics
Editor
Business Wire
1.00
0
24/10/2024
Mercado laboral
Responsabilidad Social Corporativa
Industria
Asociaciones/Profesionales
Sanidad
Biotecnología
Farmacéutica
Salud
Merz Therapeutics and World Stroke Organization Launch ‘Access to Health’ Initiative to Improve Stroke Care in Africa
Fuente
Merz Therapeutics
Editor
Business Wire
1.00
0
10/07/2024
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Fuente
Merz Therapeutics
Editor
Business Wire
1.00
0
10/07/2024
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Fuente
Merz Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0